Gleevec, the targeted cancer pill, delivers more good news to patients Dec 10, 2007
Gleevec has also been approved for the treatment of gastrointestinal stromal tumors, pediatric CML, as well as five additional rare cancers. . (EurekAlert!)
Re-engineered Gleevec Reduces Heart Risks, Study Suggests Dec 6, 2007
The new study reports pre-clinical evidence that the newly re-engineered drug is just as effective as imatinib against gastrointestinal stromal tumor (GIST) and carries significantly less risk of heart failure. Developed by Novartis Pharmaceuticals, Gleevec is approved by the U.S. Food and Drug Administration for the treatment of chronic myeloid leukemia (CML), Philadelphia-chromosome positive acute lymphoblastic leukemia and GIST. The drug targets two proteins that have been linked with cancer. (Science Daily)
Rice, M.D. Anderson collaborate on anticancer drug Dec 5, 2007
The new study, which appears in the Dec. 3 issue of the Journal of Clinical Investigation, reports pre-clinical evidence that the newly re-engineered drug is as effective as imatinib against gastrointestinal stromal tumor and carries significantly less risk of heart failure. Developed by , Gleevec is approved by the for the treatment of certain types of leukemia -- cancer of the blood -- as well as the gastrointestinal cancer. (Houston Business Journal, TX)
Infinity Announces Hedgehog Pathway Inhibitor Agreement With AstraZeneca Nov 12, 2007
The companies' lead Hsp90 inhibitor, IPI-504, has demonstrated evidence of biological activity in both gastrointestinal stromal tumors (GIST) and in non-small cell lung cancer (NSCLC). The companies expect to launch Phase 2 trials of IPI-504 as a single agent in additional tumors, as well as at least one combination study, before the end of 2007. (Primezone Releases)
PHARMA MARKET: First Out Of Gate, Nexavar Loses Ground Nov 11, 2007
These include Sutent's approved use to treat gastrointestinal stromal tumors. Wyeth's (WYE) Torisel, which received U.S. Food and Drug Administration approval to treat kidney cancer in May, had sales of $10 million for the third quarter, its first full quarter on the market. (CNNMoney.com)
OHSU turns innovations into commercial opportunities at record pace Oct 24, 2007
Heinrich was the first to identify mutations in platelet-derived growth factor receptors (PDGFR) as the cause of gastrointestinal stromal tumors in specific patient populations. MolecularMDs focus is on developing partnerships with pharmaceutical companies and physicians by providing them with clinically relevant molecular tests that help optimize therapy and improve patient outcomes. (EurekAlert! -- Business News)
Tyrosine Kinase Inhibitors for CML Oct 11, 2007
Hypothyroidism has been reported in patients treated with imatinib for metastatic medullary thyroid carcinoma or gastrointestinal stromal tumors (GIST). 2 An increase in levothyroxine replacement was necessary in some patients who had previously undergone a thyroidectomy. (New England Journal of Medicine)
Couple escapes burning truck without injury Oct 6, 2007
Last March, doctors found a malignant gastrointestinal stromal tumor in Ted s abdomen which could not be treated with chemotherapy. After surgery, doctors informed the Susans that the cancer had metastasized and spread; meaning Ted could live about a year unless cancer therapy drugs were effective. (Gaylord Herald Times, MI)
Mets reach out to longtime fan Sep 27, 2007
Sadie went to the doctor to learn that the gastrointestinal stromal tumors -- a cancer so rare her oncologist deemed her "a celebrity" -- she had beaten once before had returned to her system. The surgeon reviewing her MRI said the disease had spread to her liver, pelvis and abdominal wall. (MLB.com -- NY Mets Mets)
Thailand may override patents on some cancer drugs Sep 24, 2007
Imanitib, marketed by Novartis as Gleevec in the United States and Glivec in Europe, is used to treat leukaemia and gastrointestinal stromal tumors. Docetaxel, sold as Taxotere by Sanofi-Aventis, is used to treat lung cancer, ovarian cancer and breast cancers, while Erlotinib, marketed as Tarceva by Roche, is used to treat lung, pancreatic and other types of cancers. (Inquirer.net)
Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance Sep 14, 2007
Also at Pfizer, as Executive Director and Regulatory Site Head, she had responsibility for four therapeutic areas and led the regulatory team responsible for the registration of Sutent(R) (sunitinib malate), a drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced kidney cancer and gastrointestinal stromal tumors. Prior to Pfizer, Ms. Laudicina held senior regulatory and clinical research positions at Prometheus Laboratories, Dura Pharmaceuticals and... (PR Newswire)
Study finds heart failure is rare among leukemia patients on imatinib Sep 7, 2007
Imatinib, known by its brand name Gleevec(tm) and developed by Novartis Pharmaceuticals, is approved by the U.S. Food and Drug Administration for the treatment of chronic myelogenous leukemia (CML), Philadelphia-chromosome positive acute lymphoblastic leukemia d(ALL) and gastrointestinal stromal tumor, a rare solid tumor cancer. Imatinib is a targeted therapy that inhibits two members of a class of enzymes called tyrosine kinases, which transmit growth and survival signals in cells. (EurekAlert!)
Familial Gastrointestinal Stromal Tumors and Germ-Line Mutations Sep 6, 2007
To the Editor: Gastrointestinal stromal tumors may be sporadic or inherited in an autosomal dominant manner, alone or as a component of a syndrome associated with other tumors, such as in the context of neurofibromatosis type 1. 1 We have described seven male and five female patients (median age, 23 years) from five unrelated families who had both gastrointestinal stromal tumors and paragangliomas ... 2 This condition has been referred to as "the dyad of paraganglioma and gastrointestinal... (New England Journal of Medicine)
Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group Aug 21, 2007
Executive Vice President Jerry Fields commented, "Dr, Dhawan is a highly regarded individual who brings a unique combination of scientific and commercial perspectives together to help solve client problems. Our clients benefit from his exceptional knowledge and insight. About The Mattson Jack Group, Inc. () Formed in 1986, MattsonJack focuses its client support in three areas of Competency: Business Analytics, Brand Optimization, and Corporate Development services in the pharmaceutical and... (PR Newswire)
First Detailed View Of Molecular Structure May Usher In New Class Of Cancer Drugs Aug 8, 2007
It is also anticipated that the new family of drugs may be applied for the treatment of gastrointestinal stromal tumor (GIST) cancers that are resistant to Gleevec and Sutent. Although these drugs would target the same receptors as Gleevec and Sutent, they would do so by a different mechanism and may therefore be useful for patients who are resistant to these drugs. (Science Daily)
Paul Schaye is used to conquering physical challenges. So it's no surprise how he feels about his cancer. Aug 1, 2007
Last October, he was diagnosed with a rare form of stomach cancer called gastrointestinal stromal tumor. A tumor larger than a baseball was growing in his stomach. (Boston Globe)
Pfizer Inc UK Regulatory Announcement: Pfizer's Lyrica Receives FDA Approval for Fibromyalgia Based on Expedited Review Jun 22, 2007
In addition to Lyrica s initial approval for the management of neuropathic pain associated with diabetic peripheral neuropathy, other priority reviews included Sutent for advanced kidney cancer and gastrointestinal stromal tumors and Chantix for smoking cessation. Pfizer undertook a robust clinical development program to evaluate Lyrica s effectiveness in treating a number of conditions where there is a huge unmet medical need, said Joe Feczko, Pfizer s chief medical officer. (BusinessWire)
ChemGenex reports successful personalized dosing of Quinamed at ASCO Jun 5, 2007
One patient with gastrointestinal stromal tumor (GIST) demonstrated stable disease which was sustained over 18 monthly cycles of amonafide. Greg Collier, Ph. (EurekAlert!)
Pfizer Inc UK Regulatory Announcement: New Data Evaluating SUTENT, CP-751,871 and Axitinib in Patients with Non-Small Cell Lung Cancer Jun 4, 2007
SUTENT is a multi-kinase inhibitor approved for the treatment of advanced renal cell carcinoma (RCC) and gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. Women of child bearing age who are (or become) pregnant during therapy should be informed of the potential for fetal harm while on SUTENT.. (BusinessWire)
Infinity Announces First Quarter Results and Highlights Recent Accomplishments May 1, 2007
-- The initiation of a Phase I/II clinical trial of IPI-504, Infinity's lead anticancer agent, in non-small cell lung cancer (NSCLC) -- Continued evidence of safety, tolerability, and biological activity of IPI-504 in patients with gastrointestinal stromal tumors (GIST) in data presented at the American Society for Clinical Oncology Gastrointestinal Symposium (ASCO GI) -- Demonstration of bioavailability and preclinical efficacy for the oral formulation of IPI-504 in NSCLC as presented at the... (Primezone Releases)
Gleevec reduces recurrence in colon cancer Apr 17, 2007
The large national clinical trial, led by Dr. Ronald DeMatteo, of Memorial Sloan-Kettering Cancer Center, and conducted by a national network of researchers, treated patients with primary gastrointestinal stromal tumor (GIST), a type of tumor usually found in the stomach or small intestine. They released the early results because the study had met is primary objective of increasing recurrence-free survival. (Cancerfacts.com)
Gleevec keeps stomach tumor at bay: study Apr 13, 2007
The National Institutes of Health-funded team found that 97 per cent of patients with a stomach cancer called gastrointestinal stromal tumor of GIST who took Gleevec for one year remained cancer-free after surgery as compared to 83 percent of patients given a placebo ... The American Cancer Society says it is not known how many new gastrointestinal stromal tumors are diagnosed each year but estimated that around 1,500 malignant cases occur in the United States. (Scientific American)
Gleevec decreases cancer recurrence for patients with primary gastrointestinal stromal tumor Apr 13, 2007
Preliminary results from a large, randomized, placebo-controlled clinical trial for patients with primary gastrointestinal stromal tumor (GIST), a type of tumor usually found in the stomach or small intestine, showed that patients who received imatinib mesylate (Gleevec ) after complete removal of their tumor were significantly less likely to have a recurrence of their cancer compared to those who did not receive imatinib ... Z9001: A Phase III Randomized Double-blind Study of Adjuvant STI571... (EurekAlert!)
Sunitinib and Hypothyroidism Apr 12, 2007
3,4,5 In our group of 65 patients who were treated with sunitinib for renal-cell carcinoma or gastrointestinal stromal tumors, the. . (New England Journal of Medicine)
FDA CAPSULES Feb 13, 2007
Cardiac events with Gleevec, a drug used to treat chronic myeloid leukemia and gastrointestinal stromal tumors. Avoiding burns from electrodes and cables during MRI exams. (Newsday -- Health)
Infinity Announces Fourth Quarter and Year End 2006 Results Feb 8, 2007
Evidence of biological activity of IPI-504, Infinity's lead anticancer agent, in a Phase I clinical trial in patients with gastrointestinal stromal tumors (GIST) * Establishment of a worldwide collaboration with MedImmune, Inc. around Infinity's two lead programs, inhibitors of heat shock protein 90 (Hsp90) and the Hedgehog cell-signaling pathway * Establishment of a worldwide collaboration with Novartis on Infinity's Bcl-2 inhibitor program * Extension of a license agreement by Amgen for... (Primezone Releases)
MedImmune's Advancing Cancer Pipeline to Be Highlighted at the American Society of Hematology's Annual Meeting Dec 10, 2006
In December 2005, Infinity initiated the second Phase 1 clinical trials with IPI-504 in refractory gastrointestinal stromal tumors (GIST). Infinity has also begun developing an oral formulation of IPI-504, which if successful, could be a more convenient route of administration for cancer therapy. (PR Newswire)
5-year Study Shows Gleevec's Potency Against Chronic Myeloid Leukemia Dec 9, 2006
The outcome of the five-year study also offers lessons for physicians who are using Gleevec to treat other cancers, such as gastrointestinal stromal tumor, said Druker ... "In CML, there is the advantage that most patients get diagnosed at an early, chronic stage; whereas gastrointestinal stromal tumors are often diagnosed at a more advanced stage. Our results demonstrating Gleevec's high efficacy in CML tell us that in applying the drug to other cancers, we need to diagnose and treat patients... (Science Daily)
Gleevec(R) Demonstrates Highest Five-Year Overall Survival Rate in History of Treatment for Patients With Chronic Myeloid Leukemia Dec 7, 2006
Gleevec tablets are also indicated for the treatment of patients with KIT (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). The effectiveness of Gleevec in GIST is based on objective response rate. (PR Newswire)
Esteemed Yale professor sued over alleged sexual harassment Dec 2, 2006
A company he co-founded developed the drug Sutent/SU11248 to treat renal cancers and gastrointestinal stromal tumors that was approved by the U.S. Food and Drug Administration in January. Garceau, an administrative associate who resigned in 2004, says Schlessinger told a lewd and sexually offensive joke in July 2001, on her first day on the job. (New Haven Register, CT)
Summary for Patients Nov 7, 2006
Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors -- Desai et al. 145 (9): 660 -- Annals of Internal Medicine ... The summary below is from the full report titled "Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal Tumors." It is in the 7 November 2006 issue of Annals of Internal Medicine (volume 145, pages 660-664) ... Doctors have found that tyrosine kinase inhibitors can be used to treat certain types of stomach and... (Annals of Internal Medicine)
New Biologic Treatment For Tennis Elbow May Replace Surgery For Chronic Sufferers Oct 24, 2006
(December 16, 2004) -- Not only can positron emission tomography (PET) help evaluate treatment for gastrointestinal stromal tumors (GIST) by revealing biologic changes such as how the tumor processes the fuel that makes it. . (Science Daily)
Novartis drug wins expanded FDA approval Oct 22, 2006
The Food and Drug Administration previously approved Gleevec to treat Philadelphia chromosome-positive chronic myeloid leukemia and gastrointestinal stromal tumors. Also Friday, the FDA said Novartis was updating Gleevec's label with a precaution that describes the occasional occurrence of severe congestive heart failure and left ventricular dysfunction in patients on the drug. (Herald Online, SC -- Health)
Gleevec(R) Approved in the US for Five Rare Life-Threatening Disorders With Limited Treatment Options Oct 20, 2006
"These approvals further build and demonstrate our historical commitment to developing therapies for patients with rare diseases such as acromegaly, carcinoid syndrome and gastrointestinal stromal tumors." The FDA approvals are based on data from Novartis-sponsored clinical studies and clinical data from independent medical researchers showing the efficacy of Gleevec in the treatment of these diseases, in which there is a suggested connection between a Gleevec-sensitive pathway and a disease ...... (PR Newswire)
Breakthrough Cancer Drug Gleevec Gets Heart Precaution Oct 20, 2006
Gleevec (generic name imatinib) is approved to treat chronic myelogenous leukemia -- CML -- and gastrointestinal stromal tumors. Findings of a study reported at this year's meeting of the American Society of Clinical Oncology reported that overall survival for people with CML who took Gleevec for five years was 89 percent -- and 95 percent if only deaths related to CML were considered. (Forbes)
Gene Test May Help Treat Rare Gastric Cancer Sep 15, 2006
Since 2002, Gleevec (imatinib) has been the first-line treatment for people with gastrointestinal stromal tumors (GIST), a rare type of cancer that, when advanced, is resistant to chemotherapy. But not all patients respond well to Gleevec, and a new drug, Sutent (sunitinib), is sometimes beneficial in people who do not respond to or become resistant to Gleevec. (Health-Finder)
Imatinib and Altered Bone and Mineral Metabolism Aug 10, 2006
To the Editor: Berman and colleagues (May 11 issue)1 report their findings regarding the development of hypophosphatemia and associated changes in bone and mineral metabolism in patients with either chronic myelogenous leukemia or gastrointestinal stromal tumors who are taking imatinib. We have reviewed the global database of clinical trials sponsored by Novartis, as well as spontaneous post-marketing reports that cover approximately 200,000 patient-years of treatment with imatinib (unpublished... (New England Journal of Medicine)
Cancer Drug Gleevec May Damage Heart Jul 26, 2006
Gleevec is also approved for gastrointestinal stromal tumors or GIST, a rare type of stomach cancer. It stops the activity of a protein called Bcr-Abl, which causes the out-of-control behavior of white blood cells in CML.. (MEDLINEplus)
Leukemia drug Gleevec: Questions and answers Jul 25, 2006
Gleevec, also known as STI571, is a new drug that was approved by the Food and Drug Administration in 2001 for the treatment of chronic myeloid leukemia (CML), a cancer of white blood cells, and for the treatment of a rare form of stomach cancer called gastrointestinal stromal tumor (GIST) in 2002 ... Currently, these tumors are: gastrointestinal stromal tumor (GIST), glioma, and soft tissue sarcoma. (Food Consumer)
Cancer drug Gleevec may damage heart: study Jul 24, 2006
Gleevec, sold in Europe as Glivec, is also approved for gastrointestinal stromal tumors or GIST, a rare type of stomach cancer. It stops the activity of a protein called Bcr-Abl, which causes the out-of-control behavior of white blood cells in CML.. (ABC News -- Wire)
Jefferson scientists show 'miracle' cancer drug Gleevec can be toxic to the heart Jul 24, 2006
In Gleevec, for example, blocking the PDGF receptor is crucial to its effect in thwarting gastrointestinal stromal tumors. Designing a drug to inhibit the PDGF receptor but not ABL, then, could still work against such tumors but not cause heart problems. (EurekAlert!)
Drug Attacks Prostate Cancer In Mouse Model By Destroying Its Blood Supply Jun 8, 2006
Gleevec, developed by Novartis Pharmaceuticals Corporation, is used to treat chronic myelogenous leukemia and gastrointestinal stromal tumors. Cancer cells are biologically diverse and genetically unstable, Fidler says, so it is highly unlikely that a single therapy will prevail, necessitating a multi-modal attack on the disease. (Science Daily)
How Drug Cocktails Are Changing the Way We Treat Cancer Jun 8, 2006
The specific cancers for which Gleevec has wrought such miracles chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST) rely pretty exclusively on a pathway that Gleevec targets, making these diseases ideal victims for a targeted therapy. But breast, lung, colon and prostate cancers, the leading types of cancer in the US, aren't as accommodating. (Time.com)
New kidney-cancer treatments are hot topic at doctors meeting Jun 6, 2006
Sutent also was approved to treat gastrointestinal stromal tumors ... Bear Stearns analyst John Boris estimates 2010 Sutent sales of $920 million, which would include its use in gastrointestinal stromal tumors and possibly future indications. (MarketWatch)
Cancer Institute Study Points To Future Of Personalized Medicine Jun 5, 2006
Initially used to treat patients with chronic myelogenous leukemia, it has also proved successful in treating a rare stomach cancer called gastrointestinal stromal tumor (GIST). But imatinib doesn't work for every GIST patient, and even when it does work, many GIST patients develop resistance to it. (Science Daily)
Study: Drug curbs cancer Jun 5, 2006
Dr. Robert Mayer, a professor of medicine at Harvard Medical School said the new study "confirms as first-line therapy." He pointed to Gleevec's versatility because it is also first-line therapy for gastrointestinal stromal tumor, a rare cancer of the digestive system. Although the gastrointestinal cancer is unrelated to the leukemia, it possesses a similar enzymatic miscue that can be controlled by Gleevec. (Newsday)
Five-year study confirms Gleevec's long-term benefits Jun 5, 2006
-- People with advanced gastrointestinal stromal tumors (GIST) who take Gleevec (imatinib) for prolonged periods continue to benefit from the drug, according to a five-year study by Oregon Health ce University Cancer Institute researchers. The study was led by Charles Blanke, M.D., leader of the OHSU Cancer Institute Solid Tumors Program, with colleagues at OHSU, Dana-Farber Cancer Institute, the Fox Chase Cancer Center, and the University of Helsinki. (EurekAlert!)
Pfizer's Sutent May Help Treat Advanced Cases of Lung Cancer, Study Says Jun 4, 2006
Sutent was approved earlier this year to fight advanced kidney cancer and a rare form of stomach cancer known as gastrointestinal stromal tumors. We're very anxious to begin to add this to other agents,'' said Bruce Johnson, director of thoracic oncology at Dana-Farber Cancer Institute in Boston. (Bloomberg -- US)
A New Immune Cell and the Response to Imatinib Mesylate May 25, 2006
Tyrosine kinases are major targets of contemporary chemotherapy, and tyrosine kinase inhibitors such as imatinib mesylate (Gleevec, Novartis; formerly known as STI571) are approved for the treatment of some forms of chronic myelogenous leukemia and a rare form of stomach cancer called gastrointestinal stromal tumor. Surprisingly, some types of gastrointestinal stromal tumors refractory to the antiproliferative effects of imatinib mesylate in vitro were shown recently to respond to the drug in... (New England Journal of Medicine)
Gaither High's 'Mr. Cool' Loses Cancer Battle May 13, 2006
Cool' Loses Cancer Battle. Now we're surrounded by my friends and family, who have always been there to help us in so many ways. (Tampa Bay Online, FL -- News)
The pluses and risks of estrogen May 12, 2006
And Gleevec (imatinib mesylate), the molecularly targeted pill that has shown impressive results for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumors, showed a slight flaw. In this case, Gleevec given at high doses or to patients younger than 50 may impair bone metabolism. (CNN -- Health)
Cancer Drug Gleevec Can Interfere With Bone Growth May 12, 2006
The detection of the drug's effect on bone means patients being treated with Gleevec for either CML or intestinal cancers called gastrointestinal stromal tumors "have to be screened for abnormalities of bone," Berman said. "What Gleevec appears to do is inhibit bone synthesis and bone remodeling.". (MEDLINEplus)
Altered Bone and Mineral Metabolism in Patients Receiving Imatinib May 11, 2006
We observed that hypophosphatemia developed in some patients with either chronic myelogenous leukemia or gastrointestinal stromal tumors who were receiving imatinib ... Conclusions Hypophosphatemia, with associated changes in bone and mineral metabolism, develops in a proportion of patients taking imatinib for either chronic myelogenous leukemia or gastrointestinal stromal tumors. (New England Journal of Medicine)
Five years after approval, Gleevec underscores the promise of targeted therapy to provide sustained disease control May 10, 2006
In 2002, Gleevec was approved worldwide for the treatment of patients with unresectable and/or metastatic Kit (CD117)-positive gastrointestinal stromal tumors (GISTs) ... Gleevec tablets are also indicated for the treatment of patients with KIT (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors. (PR Newswire)
A Broken Stress Response System Can Contribute To Gleevec Resistance Apr 24, 2006
(June 10, 2004) -- A drug originally developed to block the formation of blood vessels in tumors has been shown to overcome resistance to treatment with Gleevec in patients with gastrointestinal stromal tumors. . (Science Daily)
Novartis completes submissions in US and Europe for Gleevec(R) as treatment for four rare types of cancer Apr 10, 2006
Gleevec has been shown to inhibit the function of the tyrosine kinase Bcr-Abl in Philadelphia-chromosome positive (Ph+) chronic myeloid leukemia (CML), and the receptor tyrosine kinase Kit in Kit (CD117)-positive gastrointestinal stromal tumors (GIST) ... Gleevec tablets are also indicated for the treatment of patients with KIT (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors. (PR Newswire)
New strategy developed to study disease: Reveals insights into cancer and treatment leads Mar 8, 2006
"For example, Gleevec, which is used to treat gastrointestinal stromal tumors and chronic myeloid leukemia, is the most successful magic bullet against cancer in many years and works by blocking tyrosine kinase activity," Cole says. As a next step, Cole and his colleagues plan to further examine the role of Src in cancer using their new model. (EurekAlert!)
FDA OKs Pfizer stomach, kidney cancer drug Jan 29, 2006
The once-a-day capsule is meant to treat both gastrointestinal stromal tumors, a rare stomach cancer also known as GIST, and advanced kidney cancer. Pfizer is studying the drug for use in treating other cancers, including colorectal, breast and lung cancer. (Seattle Post Intelligencer)
New cancer drug approved Jan 28, 2006
In addition to kidney cancer, the FDA approved Sutent for patients with gastrointestinal stromal tumors, or GIST, whose disease is no longer controlled by a drug called Gleevec, or who had rare but severe reactions to it. About 5,000 people are diagnosed with GIST every year, according to the FDA.. (USA Today -- Health)
